Recap: Assertio Therapeutics Q1 Earnings

Shares of Assertio Therapeutics ASRT rose 9% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 56.52% over the past year to $0.10, which beat the estimate of ($0.08).

Revenue of $20,917,000 less by 63.89% from the same period last year, which beat the estimate of $11,300,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 11, 2020

Time: 08:01 PM ET

Webcast URL: https://edge.media-server.com/mmc/p/vryis85c

Technicals

52-week high: $4.92

Company's 52-week low was at $0.55

Price action over last quarter: Up 10.80%

Company Description

Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.

ASRT Logo
ASRTAssertio Holdings Inc
$0.6055-7.13%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
12.95
Growth
27.75
Quality
Not Available
Value
78.27
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Comments
Loading...